RESTYLANE
FDA premarket approval P040024/S103 · decided 2019-05-17
Approval details
- PMA number
- P040024
- Supplement
- S103
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- RESTYLANE
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Q-Med AB
- Date received
- 2018-11-01
- Decision date
- 2019-05-17
- Days to decision
- 197 days
- Decision code
- APPR
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Uppsala
- Statement
- Approval for revisions to the clinician and patient labeling of Restylane to include updated safety information based on post marketing surveillance data.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.